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Background. Xenon-in-oxygen is a high density gas mixture and may improve PaO2/FiO2 ratio in morbidly obese patients
uniforming distribution of ventilation during anesthesia. Methods. We compared xenon versus sevoﬂurane anesthesia in twenty
adult morbidly obese patients (BMI > 35) candidate for roux-en-Y laparoscopic gastric bypass and assessed PaO2/FiO2 ratio at
baseline, at 15min from induction of anaesthesia and every 60min during surgery. Diﬀerences in intraoperative and postoperative
data including heart rate, systolic and diastolic pressure, oxygen saturation, plateau pressure, eyes opening and extubation time,
Aldrete score on arrival to the PACU were compared by the Mann-Whitney test and were considered as secondary aims. Moreover
the occurrence of side eﬀects and postoperative analgesic demand were assessed. Results.I nx e n o ng r o u pP a O 2 - F i O 2r a t i ow a s
signiﬁcantly higher after 60min and 120min from induction of anesthesia; heart rate and overall remifentanil consumption were
lower; the eyes opening time and the extubation time were shorter; morphine consumption at 72hours was lower; postoperative
nauseawasmorecommon.Conclusions.XenonanesthesiaimprovedPaO2/FiO2ratioandmaintaineditsdistinctiverapidrecovery
times and cardiovascular stability. A reduction of opioid consumption during and after surgery and an increased incidence of
PONV were also observed in xenon group.
1.Introduction
Arterial oxygenation may decrease during anesthesia with
mechanical ventilation [1, 2]. This phenomenon is more
evident in obese than in normal-weight patients [3, 4].
Increase in body mass index (BMI) is directly related to
the impairment of arterial oxygenation, which is mainly
attributable to development of ventilation-perfusion (V/Q)
mismatches and intrapulmonary shunt (i.e., atelectasis); in
fact this is more common during laparoscopy [5, 6]. For
these reasons in morbidly obese patients, various strategies
have been proposed to improve gas exchange during general
anesthesia[7,8].XenonisaN-Methyl-D-Aspartate(NMDA)
receptor blocking agent which has become an alternative to
the currently used inhaled anaesthetics [9, 10]. The element
xenon is a noble gas, has no harmful environmental eﬀects,
is associated with cardiovascular stability [9–11], and owns
organoprotective properties, being able to interact with a
variety of molecular targets. Several experimental studies
have demonstrated a reduction in cerebral and myocardial
infarction size after xenon inhalation and the up-regulation
of several genes involved in cellular surviving pathways
in several tissues [12–15]. Xenon has the lowest blood-
gas coeﬃcient (0.115) of all known anaesthetics making
induction and recovery from anesthesia very fast [16].
Furthermore, “xenon in oxygen” is a high-density mixture
that increases airway pressure and resistance by a rising the
Reynold’s number [17], but this reproducible eﬀect does not
assume certain clinic implications [18]. On the contrary, as
elegantly described by Wood et al., breathing gas mixtures
with increased density may cause a reduction of alveolar-
arterialoxygendiﬀerence(AaDO2)andimprovesrespiratory
performances and distribution of ventilation, minimizing
V/Q variances [19]. Despite arterial oxygen partial pressure2 Journal of Obesity
(PaO2), hemoglobin oxygen saturation (SaO2) and AaDO2
are clinical indices commonly used for assessing lung
function, as described by Zetterstr¨ om et al.;the ratio of PaO2
to the inspired oxygen fraction (PaO2/FiO2 ratio) seems
the most accurate and independent oﬀ all extrapulmonary
variables [20, 21].
In this paper, we present for the ﬁrst time intra
and postoperative data on respiratory function, hemody-
namic status, and recovery times from morbidly obese
patients (BMI> 35) receiving xenon-remifentanil (XR) or
sevoﬂurane-remifentanil (SR) anaesthesia. In particular, we
testedthehypothesisthatxenonanesthesiaisabletoimprove
PaO2/FiO2 ratio. Furthermore, we tested the hypothesis
that xenon, even in morbidly obese patients, maintains its
pharmacologic properties characterized by cardiovascular
stability and rapid recovery times. The incidence of side
eﬀects and the postoperative analgesic demand were also
assessed.
2. Methods
The study was a prospective randomised partially blinded
controlled trial. The protocol was approved by the local
ethics committee, and all patients gave their informed
consent before participation. A total of 20 adult morbidly
obese patients scheduled for roux-en-Y laparoscopic gastric
bypass were randomly recruited. Exclusion criteria were
ASA IV, age <18 or >60yr, Mallampati IV. Monitoring
included ECG, pulse oximetry, invasive arterial pressure,
temperature, end-tidal carbon dioxide, oxygen and xenon
concentrations. All intraoperative continuous variables were
recorded every 3min. Arterial blood gas analysis was per-
formed in the preoperative assessment, at 15min after the
induction of anaesthesia, and every 60min during surgery.
The A-line ARX index (AAI) was also monitored (AEP
monitor, Alaris Medical Systerns, Inc, San Diego, CA) to
provide information about depth of anaesthesia. Monitoring
was performed to ensure AAI values <30, and data were
recorded every 5min. After preoxygenation with O2 100%
for 5min, anaesthesia was induced in all patients with
propofol 2mg/kg i.v. dosed on real body weight (RBW)
and remifentanil 0.5mcg/kg/min dosed on ideal body weight
(IBW) according to Lorenz’s formula (Ideal weight = [height
in cm-100] – [height in cm-150]/2) by i.v. infusion over
60sec. All patients were submitted to direct laringoscopy
for intubation. Since mask ventilation was uncomplicated
an i.v. bolus of cisatracurium 0.2mg/kg IBW was given
and intubation performed. All patients received remifen-
tanil continuous infusion after intubation starting with
0.25mcg/kg/min IBW and cisatracurium 0.02mg/kg IBW
every 40min titrated to clinical needs. No cisatracurium was
given after the end of 2nd anastomosis (30 minutes before
end of surgery). In both groups, a closed-circuit anaesthesia
machine (Felix Dual, Taema, France) was used for gas
delivery.Xe(LenoXe,Airliquide)administrationstartedafter
accurate patient’s denitrogenation (FiO2 >97%, FeO2 >92);
midazolam 0.05mg/Kg IBW was given in order to keep AAI
<30 for the time, 7 to 10 minutes, occurring to reach 40%
FeXe in closed circuit. Hypnosis was then maintained using
Xe60–65%inoxygen.InSRgroup,hypnosiswasmaintained
with sevoﬂurane 1MAC in a mixture of oxygen-air. In both
groups, ventilation was pressure-controlled (PCV), with
FiO2 35%, Peep 5, Vt 8–10ml/kg IBW in order to maintain
an end-expiratory carbon dioxide partial pressure (EtCO2)
at 4.8–6.0kPa. Haemodynamic parameters were maintained
within 20% of preoperative values by adjusting remifentanil
infusion accordingly. Normothermia (35.5–37.0◦C) was
achieved using warming blankets. AAI <30 was kept until
the bandaging of the surgical ﬁelds were completed then
anaesthesia was discontinued. The eyes opening time started
with the closure of gas delivery and ended with eyes opening
on command. When an adequate spontaneous ventilation,
with an EtCO2 at 5.3–6.6kPa, was maintained, the trachea
was extubated and the patient was transferred into the post
anesthesia care unit (PACU). A patient-controlled analgesia
(PCA) device was then connected to a venous line delivering
morphine on command.
2.1. Statistics and Sample Size Calculation. We decided to
consider as clinically relevant a diﬀerence of 60 on PaO2-
FiO2 ratio among the groups, measured at 120 minutes after
induction. Assuming a mean PaO2-FiO2 ratio (standard
deviation) of 370 (55) in xenon group and 310 (35) in
the other group, we estimated a sample size of 10 patients
per group enough to detect a diﬀerence of 60, at 5%
level of signiﬁcance with 80% power. We veriﬁed the
existence of no signiﬁcant diﬀerences in patient’s demo-
graphic characteristics (age, sex, BMI), preoperative clinic
characteristics, and duration of anaesthesia using the Mann-
Whitney test for continuous variables and the Fisher’s exact
test for categorial variables. Diﬀerences in intraoperative and
postoperative data including heart rate, systolic and diastolic
pressure, oxygen saturation, plateau pressure, eyes opening
and extubation time, and Aldrete score in the PACU were
compared by the Mann-Whitney test and were considered
as secondary aims. The existence of a signiﬁcant diﬀerence
on morphine consumption after 72 hours between the two
groups was compared, and the occurrence of adverse events
(hypertension, hypotension, bradycardia, PONV, postoper-
ative headache, awareness) was ﬁnally evaluated. Statistical
analysis was performed using Stata, version 9.2, on a Mac OS
X operating system. Results were considered signiﬁcant with
a P value <. 05. All data are presented as median (range).
3. Results
The two groups were comparable as shown in Table 1.N o
signiﬁcant diﬀerence was recorded in anesthesia duration
among the two groups, 150 (120–190)min in SR group and
152.5 (120–220)min in XR group; P = .849. Intraoperative
data are shown in Table 2: there was no diﬀerence among
the two groups in PaO2-FiO2 ratio at 15min after the
induction of anesthesia, but in XR group, PaO2-FiO2 ratio
was signiﬁcantly higher after 60 and 120 min. Heart rate was
signiﬁcantly lower in XR group, while systolic pressure was
signiﬁcantly lower in SR group. No signiﬁcant diﬀerences
were recorded in diastolic pressure and oxygen saturation
among the two groups; plateau pressure was signiﬁcantlyJournal of Obesity 3
Table 1: Baseline data.
SR XR P
Age (yr) 47.5 (19–57) 41 (23–49) .272
BMI 50.5 (39–71) 53 (42–83) .519
Sex (males/females) 6/4 8/2 .628
Heart rate (bpm) 87.5 (65–110) 85.5 (56–100) .570
Oxygen saturation (%) 95 (91–100) 95.5 (89–98) .623
Systolic pressure (mmHg) 160 (120–168) 137.5 (115–175) .178
Diastolic pressure (mmHg) 86 (65–100) 87.5 (75–95) .705
PaO2-FiO2 ratio (on air) 350 (307–394) 325.5 (302–392) .449
Data are presented as median (range) for continuous variables; the number of males and females in each group is reported. P<. 05 with Mann-Whitney test
was considered signiﬁcant.
Table 2: Intraoperative data.
SR XR P
PaO2-FiO2 ratio 15min 282 (195–320) 260 (212–302) .272
PaO2-FiO2 ratio 60min 301.5 (220–318) 350.5 (234–412) .041
PaO2-FiO2 ratio 120min 326.5 (234–372) 405.5 (278–432) .002
Heart rate (bpm) 78 (59–94) 57.5 (48–71) .001
Systolic pressure (mmHg) 106.5 (94–124) 121.5 (110–148) .008
Diastolic pressure (mmHg) 67.5 (58–83) 69 (62–78) .545
Oxygen saturation (%) 96 (93–97) 95.5 (94–97) .477
Plateau pressure (mmH2O) 27 (25–28) 35 (32–37) .0001
Remifentanil usage (mcg) 1597.5 (1080–2425) 762.5 (415–1460) .0001
Data are presented as median (range). P<. 05 with Mann-Whitney test was considered signiﬁcant.
Table 3: Postoperative data.
SR XR P
Eyes opening time (min) 7.6 (5.5–11.7) 2.7 (1.6–4.2) .0002
Extubation time (min) 9.4 (6.7–13.7) 2.9 (1.7–4.9) .0002
Aldrete score (PACU admission) 9 (8–10) 9 (8–10) 1.000
Morphine demand 72 hours (mg) 26 (13–41) 9.5 (0–16) .0016
Data are presented as median (range). P<. 05 with Mann-Whitney test was considered signiﬁcant.












H y p e r t e n s i o n 0011
Hypotension 2 2 0 0
Bradycardia 1 2 2 4
PONV 1 1 4 6
Postoperative
headache 1122
Awareness 0 0 0 0
Bradycardia was intended a>20% deviation from mean baseline, hypertension a>20% deviation from mean systolic baseline with stable heart rate and no
other signs of low depth of anaesthesia and hypotension a>20% deviation from mean systolic baseline.4 Journal of Obesity
higher and overall remifentanil consumption signiﬁcantly
lower in XR group. Postoperative data are shown in Table 3:
the eyes opening time and the extubation time were signif-
icantly shorter in XR group; morphine consumption after
72 hours was signiﬁcantly lower in XR group. No diﬀerence
among groups was noticed in Aldrete score on admission
to the PACU. Adverse events occurrence is exposed in
Table 4: hypertension, bradycardia, postoperative headache
occurred rarely but more frequently in XR group; PONV
was more common in XR group and only nausea was
noticed; no patient experienced vomiting in the two groups.
Hypotension occurred rarely but more frequently in SR
group. No patient experienced awareness.
4. Discussion
In this study, we verify that xenon anesthesia is associated
with better arterial oxygenation and cardiovascular stability
in morbidly obese patients. As argued by Wood et al [19]
the eﬀect on AaDO2 of a high-density gas mixture may be
due to a more uniform distribution of ventilation during
anesthesia; however, xenon, which pharmacologically is a
NMDA receptor antagonist, is not considered a biologically
inert gas [12–15, 22, 23] and the improvement of PaO2/FiO2
ratio may be related not only to “high-density eﬀect” of
the inhaled mixture but also to its organoprotective and
preconditioning eﬀects [12–15]. Recovery times recorded
after xenon anesthesia were faster according to the blood-gas
coeﬃcient of the molecule [16]; no considerable diﬀerence
was noticed with respect to normal-weight patients trials,
taking into account the sample size of our study [9]. Xenon
anesthesia was characterized by a signiﬁcative higher arterial
systolic pressure and by a minimal variation from preoper-
ative baseline (Tables 1 and 2). Heart rate was lower; more
evident were bradycardia, hypertension, and incidence of
postoperative nausea; airway pressure was signiﬁcantly and
constantly increased. All these data are aligned to normal-
weight patients trials ﬁndings and experimental literature
about xenon anesthesia [9, 17, 18, 24].
An unexpected and signiﬁcative reduction of opioid
consumption in xenon group was found. Xenon exerts a
potent analgesic action due to NMDA receptor inhibition
[25] which may explain the lower overall remifentanil
consumption during surgery; however, wash in and wash
out of xenon are very fast [9, 13], and NMDA receptor
blocking ability may not explain an eﬀect on pain pathways
up to 72 hours. Nowadays the evidence is that xenon is
able to modulate long-term pathways [12, 14, 22]w h i c h
are considered the end eﬀectors producing the long-term
organoprotective eﬀects of the gas. It is possible that a long-
term modulation of pain could be inserted in such scenario
but further studies are required.
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